Pediatric gastroenterology, hepatology & nutrition · 2026
Efficacy and Safety of High-Dose Multimatrix Mesalazine in Pediatric Patients with Mild-to-Moderate Active Ulcerative Colitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shimizu Toshiaki, Iwama Itaru, Kakiuchi Toshihiko, Abukawa Daiki, Kumagai Hideki, Iwata Naomi, Takatsu Masahiro, Nishimura Kanako, Matsuda Akiko, Hayashi Koichi, Mizuochi Tatsuki
Аннотация
PURPOSE: This study aimed to investigate the efficacy and safety of high-dose multimatrix mesalazine in pediatric patients with active ulcerative colitis (UC).
METHODS: This was an open-label, uncontrolled, multicenter trial in Japan that included 27 patients aged <17 years with mild-to-moderate active UC. The participants were treated with multimatrix mesalazine at a dose of 80 mg/kg orally once daily for 8 weeks. The primary efficacy endpoint was the achievement of clinical remission, measured based on the ulcerative colitis disease activity index (UC-DAI) score.
RESULTS: In the full analysis set, the clinical remission rate based on the UC-DAI score at the end of treatment was 25.9% (two-sided 95% confidence interval [CI]: 11.1%, 46.3%; n=7/27). The lower limit of the two-sided 95% CI exceeded the efficacy threshold (10%), which was predefined based on the placebo group results from clinical studies involving patients with UC. The incidence of adverse events (AEs) was 66.7% (n=18/27) and that of drug-related AEs was 18.5% (n=5/27). No fatalities were reported. Among the study drug-related AEs, only drug intolerance (n=2) was classified as severe, serious, or led to study drug discontinuation.
CONCLUSION: This study demonstrates the clinically meaningful efficacy of high-dose multimatrix mesalazine in the treatment of mild-to-moderate active pediatric UC in Japan. No noteworthy safety concerns beyond the known risks associated with mesalazine were noted.
METHODS: This was an open-label, uncontrolled, multicenter trial in Japan that included 27 patients aged <17 years with mild-to-moderate active UC. The participants were treated with multimatrix mesalazine at a dose of 80 mg/kg orally once daily for 8 weeks. The primary efficacy endpoint was the achievement of clinical remission, measured based on the ulcerative colitis disease activity index (UC-DAI) score.
RESULTS: In the full analysis set, the clinical remission rate based on the UC-DAI score at the end of treatment was 25.9% (two-sided 95% confidence interval [CI]: 11.1%, 46.3%; n=7/27). The lower limit of the two-sided 95% CI exceeded the efficacy threshold (10%), which was predefined based on the placebo group results from clinical studies involving patients with UC. The incidence of adverse events (AEs) was 66.7% (n=18/27) and that of drug-related AEs was 18.5% (n=5/27). No fatalities were reported. Among the study drug-related AEs, only drug intolerance (n=2) was classified as severe, serious, or led to study drug discontinuation.
CONCLUSION: This study demonstrates the clinically meaningful efficacy of high-dose multimatrix mesalazine in the treatment of mild-to-moderate active pediatric UC in Japan. No noteworthy safety concerns beyond the known risks associated with mesalazine were noted.